Pricing and Reimbursement

Orphan drugs inherently face a number of challenges in their development and value assessment. In this blog post, we describe the Mechanism of Coordinated Action (MoCA) initiative, and discuss why it can be beneficial to all parties involved and how it can improve decision making for – and access to – orphan drugs in European countries.

OHE Consulting produces a report on Measuring UK Medicines Expenditure in the Context of the 2014-18 PPRS.

The OHE has published a report exploring the impact on payers, patients and innovators of differential prices for different uses of pharmaceuticals.

OHE Consulting produces a report critiquing a paper by Hill et al. (2018) on estimated costs of production for the WHO Essential Medicines List.

Meet some of the OHE team at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2018 conference in Baltimore, 19-23 May.

Just published are two new reports that explore the use of real world evidence for coverage and formulary decisions. The publications represent 1) the background paper to the 2017 ICER Membership Policy Summit and 2) a follow up paper based on the discussion at the Summit.

A recently published editorial by OHE’s David Mott considers whether quantitative patient preference data has a role to play in HTA decision making.

A recent issue of Value in Health contains the ISPOR Special Task Force Report on US Value Assessment Frameworks. In this blog post, we summarise the Task Force Report and pick up key points made in the various response articles. We also highlight further OHE work in this area.

This report analyses patient access in the UK to new medicines authorised via the centralised procedure between 2011 and 2016.

Drug prices in the US might overstate pharmaceuticals' long-run cost up to 75%. True long-term costs then must be considered by market access and policy decisions.